

CITATION REPORT

List of articles citing

Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials

DOI: 10.1016/j.ijcard.2016.11.181

International Journal of Cardiology, 2017, 228, 352-358.

Source: <https://exaly.com/paper-pdf/67634702/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
57	Pathophysiological explanation of cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors by neurotrophic theory. <i>Medical Hypotheses</i> , 2017 , 102, 61-64	3.8	1
56	Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2017 , 16, 29	8.7	63
55	Does Gender Influence the Cardiovascular Benefits Observed with Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis. <i>Cardiology and Therapy</i> , 2017 , 6, 129-132	2.8	5
54	Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2017 , 43, 299-313	5.4	16
53	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Medicine</i> , 2017 , 130, S18-S29	2.4	37
52	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Cardiology</i> , 2017 , 120, S17-S27	3	54
51	Incretin-based therapy for type 2 diabetes: What have we learned from the meta-analyses?. <i>International Journal of Cardiology</i> , 2017 , 239, 19	3.2	1
50	Comorbidities in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017 , 243, 35-66	3.2	21
49	The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective. <i>Clinical Cardiology</i> , 2017 , 40, 970-973	3.3	4
48	Review article: new treatments in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 494-507	6.1	41
47	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. <i>JAMA Cardiology</i> , 2017 , 2, 1025-1029	16.2	217
46	Insulin and Other Hypoglycemic Drugs. <i>Side Effects of Drugs Annual</i> , 2017 , 435-446	0.2	1
45	SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. <i>Acta Diabetologica</i> , 2018 , 55, 503-514	3.9	91
44	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. <i>Medicina Clínica (English Edition)</i> , 2018 , 150, 275-281	0.3	1
43	Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit. <i>Cardiology in Review</i> , 2018 , 26, 312-320	3.2	4
42	Glucose-lowering treatment in cardiovascular and peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018 , 39, 86-98	5.1	4
41	Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 495-502	3.9	66

40	Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	66
39	Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. <i>International Journal of Cardiology</i> , 2018 , 254, 291-296	3.2	23
38	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. <i>Medicina Clínica</i> , 2018 , 150, 275-281	1	4
37	Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. <i>European Heart Journal</i> , 2018 , 39, 2368-2375	9.5	26
36	Computational revelation of binding mechanisms of inhibitors to endocellular protein tyrosine phosphatase 1B using molecular dynamics simulations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2018 , 36, 3636-3650	3.6	14
35	Empagliflozin across the stages of diabetic heart disease. <i>European Heart Journal</i> , 2018 , 39, 371-373	9.5	6
34	Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients. <i>Current Cardiology Reports</i> , 2018 , 20, 65	4.2	6
33	Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. <i>Circulation Research</i> , 2018 , 122, 1439-1459	15.7	148
32	Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. <i>Diabetes Therapy</i> , 2018 , 9, 1945-1958	3.6	13
31	Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019 , 12, 2125-2136	3.4	26
30	Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. <i>Cardiovascular Diabetology</i> , 2019 , 18, 112	8.7	73
29	Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?. <i>American Journal of Medicine</i> , 2019 , 132, 692-697	2.4	19
28	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. <i>Circulation Research</i> , 2019 , 124, 1520-1535	15.7	59
27	Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2019 , 21, 45	4.2	18
26	Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019 , 9, e022577	3	89
25	The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1283-1295	2.5	7
24	Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. <i>Cardiovascular Research</i> , 2019 , 115, 266-278	9.9	27
23	[Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms : A systematic review]. <i>Herz</i> , 2021 , 46, 151-158	2.6	

22	Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. <i>Cardiology in Review</i> , 2020 , 28, 219-235	3.2	4
21	Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism. <i>Annals of Medicine</i> , 2020 , 52, 178-190	1.5	0
20	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. <i>Current Vascular Pharmacology</i> , 2020 , 18, 125-138	3.3	3
19	SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study. <i>Current Cardiology Reviews</i> , 2020 , 16, 258-265	2.4	1
18	SGLT2 inhibitors and the risk of diabetic ketoacidosis among adults with Type 2 Diabetes: A systematic review and meta-analysis.		1
17	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. <i>Current Diabetes Reports</i> , 2021 , 21, 15	5.6	11
16	Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Canadian Journal of Diabetes</i> , 2021 ,	2.1	4
15	Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
14	Sodium-glucose cotransporter-2 inhibitors for type 2 diabetes mellitus in adults: An overview of 46 systematic reviews. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2289-2302	6.7	3
13	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. <i>Drugs</i> , 2021 , 81, 1491-1511	12.1	6
12	Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 2 Diabetes Mellitus. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021 ,	3.2	0
11	Reporting and methodological quality of systematic reviews and meta-analysis with protocols in Diabetes Mellitus Type II: A systematic review. <i>PLoS ONE</i> , 2020 , 15, e0243091	3.7	4
10	Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data. <i>Journal of Clinical Medicine Research</i> , 2017 , 9, 605-612	2.9	13
9	Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes. <i>Annals of Translational Medicine</i> , 2017 , 5, 470	3.2	3
8	Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. <i>Current Pharmaceutical Design</i> , 2020 , 26, 5911-5932	3.3	1
7	Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. <i>International Journal of Endocrinology and Metabolism</i> , 2019 , 17, e84353	1.8	18
6	Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism. <i>Journal of Lipid and Atherosclerosis</i> , 2018 , 7, 21	3	
5	Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study. <i>Annals of Translational Medicine</i> , 2018 , 6, 55	3.2	3

4	SGLT-2i and Cardiovascular Prognosis. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3905-3907	3.3	0
3	Complementary and Alternative Medicine for the Treatment of Diabetes and associated Complications: A Review on Therapeutic Role of Polyphenols. <i>Phytomedicine Plus</i> , 2021 , 100188		5
2	Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies. <i>European Journal of Clinical Pharmacology</i> ,	2.8	0
1	The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. 2023 , 22, 133-140		0